Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate)
- Development stage
- Phase 2
- Lead developer
- Accuitis
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ACU-D1 is a topical small molecule drug that acts as a first-in-class inhibitor of the 26S proteasome. It is being developed primarily for the treatment of moderate to severe rosacea. The active ingredient is pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate). In clinical trials, ACU-D1 demonstrated significant efficacy in reducing inflammatory lesions and erythema associated with rosacea. Its mechanism involves inhibition of the 26S proteasome and NF-kappa B signaling pathways, which are implicated in inflammation. The drug has shown a favorable safety profile in phase II studies and may also be under investigation for HPV-associated lesions in HIV-positive individuals[1][2][4][5][7].
- Other names
- pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate)
02
Targets
26S proteasome
Beyond the preview
Go deeper on pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate).